[go: up one dir, main page]

EP2010513A2 - Nouveaux composés cristallins - Google Patents

Nouveaux composés cristallins

Info

Publication number
EP2010513A2
EP2010513A2 EP07727956A EP07727956A EP2010513A2 EP 2010513 A2 EP2010513 A2 EP 2010513A2 EP 07727956 A EP07727956 A EP 07727956A EP 07727956 A EP07727956 A EP 07727956A EP 2010513 A2 EP2010513 A2 EP 2010513A2
Authority
EP
European Patent Office
Prior art keywords
oxo
tetrahydro
acid
crystalline
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07727956A
Other languages
German (de)
English (en)
Inventor
Uwe Ries
Sonja Sproll
Ulrike Werthmann
Andreas Zopf
Günther HUCHLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of EP2010513A2 publication Critical patent/EP2010513A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to the novel crystalline compounds A of the general formula I.
  • a 1 , A 2 , A 3 , X, Y 1 , Y 2 and Y 3 are as defined in claim 1 and which are present in the form of their physiologically tolerable salts with acids, the acids being selected from group B. from hydrochloric, hydrobromic, sulfuric, phosphoric, benzenesulfonic, p-toluenesulfonic, maleic, succinic, fumaric, D - (-) - tartaric, L - (+) - tartaric, naphthalene-2-sulfonic and naphthalene-1, 5-disulfonic acid , as well as the polymorphs, the corresponding solvates and hydrates.
  • the present invention relates to CGRP antagonists, which are in the form of stable crystalline derivatives and are suitable for the treatment of headaches, in particular for the treatment of migraine.
  • the pharmacologically valuable properties of the compounds according to the invention represent the basic requirement for effective use of the compound as a medicament. However, an active ingredient must still meet other requirements in order to be used as a medicament. These parameters are largely related to the physicochemical nature of the drug.
  • examples of these parameters are the active stability of the starting material under various environmental conditions, stability in the course of preparation of the pharmaceutical formulation, and stability in the final compositions of the drug.
  • the drug used to make the drug compositions should therefore have high stability, which must be ensured even under different environmental conditions. This is absolutely necessary in order to prevent the use of pharmaceutical compositions in which, in addition to the actual active substance, for example, degradation products thereof are contained. In such a case, an active ingredient content found in pharmaceutical formulations could be lower than specified.
  • Moisture-prone drugs must be protected from moisture during storage, for example by adding suitable drying agents or by storing the drug in a humidity protected environment.
  • the ingestion of moisture may reduce the level of drug during manufacture if the drug is exposed to the environment without any protection from moisture.
  • a drug should only be slightly hygroscopic.
  • solubility of the active ingredient Another criterion which, depending on the choice of formulation or the choice of the preparation process of the formulation of possibly outstanding importance, is the solubility of the active ingredient. If, for example, drug solutions (for example for infusions) are provided, adequate solubility of the active substance in physiologically compatible solvents is indispensable. Also for orally administered drugs sufficient solubility of the drug is of great importance.
  • a first object of the present invention relates to the compounds of the above general formula I, in which
  • a 2 is -NH 2 , -OH or -C 2 H 5 ,
  • X is -CH 2 -, -NH- or -O-,
  • Y 3 is -CH 2 -, -N (CH 3 ) - or -O-,
  • acids being selected from the group B consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, benzenesulphonic acid, p-toluenesulphonic acid, maleic acid, succinic acid, fumaric acid, D - (-) Tartaric acid, L - (+) - tartaric acid, naphthalene-2-sulfonic acid and naphthalene-1, 5-disulfonic acid, as well as the polymorphs, the corresponding solvates and hydrates.
  • a second aspect of the present invention relates to the novel crystalline CGRP antagonists A of general formula I which are selected from the group consisting of
  • acids B selected from hydrochloric, hydrobromic, sulfuric, phosphoric, benzenesulphonic, p-toluenesulphonic, maleic, succinic, fumaric, D - (-) - tartaric, L - (+) Tartaric acid, naphthalene-2-sulfonic acid and naphthalene-1, 5-disulfonic acid, as well as the polymorphs, the corresponding solvates and hydrates.
  • acids B selected from hydrochloric, hydrobromic, sulfuric, phosphoric, benzenesulphonic, p-toluenesulphonic, maleic, succinic, fumaric, D - (-) - tartaric, L - (+) Tartaric acid, naphthalene-2-sulfonic acid and naphthalene-1, 5-disulfonic acid, as well as the polymorphs, the corresponding solvates and hydrates.
  • the compounds of the invention are characterized by a high degree of stability and very readily soluble in physiologically acceptable solvents.
  • the crystalline salts are each characterized by a characteristic melting point which was determined by means of differential scanning calorimetry (DSC: evaluation via onset temperature or peak maximum, heating rate: 10 ° C./min).
  • DSC differential scanning calorimetry
  • the values of the individual compounds listed in Table 1 were determined by means of a DSC 821 from Mettler Toledo.
  • Table 1 Melting points of the crystalline salts according to the invention
  • Another preferred subject matter of the present invention therefore relates to the crystalline salts according to the invention, each characterized by their characteristic melting point.
  • Another preferred object relates to the crystalline compound (3d), characterized by a water content between 1.8 and 2.2%.
  • Table 12a X-ray powder reflections and intensities (normalized) of the compound (3a) - polymorph 1
  • Table 13a X-ray powder reflections and intensities (normalized) of the compound (3b) - polymorph 1
  • Table 13b X-ray powder reflections and intensities (normalized) of compound (3b) - polymorph 2
  • the present invention relates to crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (f?).
  • -1- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrochloride (2d), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d 7.59 ⁇ , 5.78 ⁇ , 4.95 ⁇ , 4.69 ⁇ , 4.59 ⁇ , 4.12 ⁇ and 3.73 ⁇ .
  • the preparation of the crystalline salt of the invention 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepine-3 -yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethyl- phenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3 /?) -2,3-dihydroxybutanedioate (3d), comprising the following steps :
  • the solvent used in step (a) is methanol, ethanol, propanol, isopropanol or a mixture of these solvents, ethanol or isopropanol or a 1: 1 mixture of ethanol and isopropanol being preferred according to the invention.
  • the solvent in step (a) is used in an amount of 2 to 5 ml / mmol of base used, preferably in an amount of 3 to 4 ml / mmol of base used.
  • step (a) The suspension formed in step (a) is then heated to a temperature of 50 to 60 ° C.
  • the solvent used in step (b) is methanol, ethanol, propanol, isopropanol or a mixture of these solvents, ethanol or isopropanol or a 1: 1 mixture of ethanol and isopropanol being preferred according to the invention.
  • the solvent in step (b) is added in an amount of 2 to 5 in L / mmol of base used, preferably in an amount of 3 to 4 mL / mmol of base used.
  • step (b) The reaction mixture obtained in step (b) is then heated to a temperature of 70 to 80 ° C, preferably to a temperature of 74 to 76 ° C, heated.
  • the solvent used in step (a) is ethanol and the solvent used in step (b) is isopropanol.
  • the solvent used in step (c) is an amount of water equivalent to the amount of tartaric acid used.
  • the water is used in an amount of 0.9 to 1.1 g / g of tartaric acid, preferably in an amount of 1.0 g / g of tartaric acid used.
  • step (c) 0.9 eq to 1.1 eq, preferably 1.0 eq, of the acid are used in step (c), in each case based on the amount of base used.
  • step (c) the solution formed in step (c) can be seeded with the desired form of the tartrate (3d).
  • a third object of the present invention is its use as a drug because of the pharmaceutical activity of the crystalline salts.
  • the compounds according to the invention and their salts with physiologically tolerated acids are thus suitable for the acute and prophylactic treatment of headaches, in particular migraine, cluster headache and tension-type headaches.
  • the compounds according to the invention also have a positive influence on the following diseases: non-insulin-dependent diabetes mellitus ("NIDDM”), cardiovascular diseases, morphine tolerance, Clostridium toxin-related diarrheal diseases, skin disorders, especially thermal and radiation-related skin damage including sunburn, skin, prurigo, pruriginous toxidermias as well as severe itching, inflammatory diseases, eg inflammatory joint diseases (osteoarthritis, rheumatoid arthritis, neurogenic arthritis), generalized soft tissue rheumatism (fibromyalgia), neurogenic inflammations of the oral mucosa, inflammatory lung diseases, allergic rhinitis, asthma, COPD, diseases associated with excessive vasodilation and consequent reduced tissue perfusion, e.g.
  • NIDDM non-insulin-dependent
  • Shock and sepsis chronic pain disorders, e.g. diabetic neuropathies, chemotherapy-induced neuropathies, HIV-induced neuropathies, postherpetic neuropathies by tissue trauma-induced neuropathies, trigeminal neuralgia, temporomandibular dysfunctions, complex regional pain syndrome (CRPS), back pain, and visceral diseases, preferably irritable bowel syndrome (IBS) and inflammatory bowel syndrome.
  • chronic pain disorders e.g. diabetic neuropathies, chemotherapy-induced neuropathies, HIV-induced neuropathies, postherpetic neuropathies by tissue trauma-induced neuropathies, trigeminal neuralgia, temporomandibular dysfunctions, complex regional pain syndrome (CRPS), back pain, and visceral diseases, preferably irritable bowel syndrome (IBS) and inflammatory bowel syndrome.
  • IBS irritable bowel syndrome
  • the compounds according to the invention have a soothing effect on pain conditions in general.
  • the symptoms of menopausal, caused by vasodilation and increased blood flow hot flushes of estrogen-deficient women and hormone-treated prostate cancer patients and castrates is the present CGRP antagonists Preventive and acute-therapeutically favorably influenced treatment application, whereby this therapy approach is characterized by side effect poverty before the hormone substitution.
  • the compounds according to the invention are preferably suitable for the acute and prophylactic treatment of migraine and cluster headache, for the treatment of irritable bowel syndrome (IBS) and for the preventive and acute therapeutic treatment of hot flushes of estrogen-deficient women.
  • IBS irritable bowel syndrome
  • the dosage required to achieve a corresponding effect is advantageously from 0.0001 to 3 mg / kg body weight, preferably from 0.01 to 1 mg / kg body weight, when administered intravenously or subcutaneously, and 0.01 to 10 mg / kg body weight when administered orally, nasally or by inhalation. preferably 0.1 to 10 mg / kg of body weight, one to three times daily.
  • Another object of the invention is the use of the compounds of the invention as valuable tools for generating and purifying (affinity chromatography) of antibodies and, after appropriate radioactive labeling, for example by tritiation of suitable precursors, for example by catalytic hydrogenation with trithium or replacement of halogen atoms by tritium, in RIA and ELISA assays and as diagnostic and analytical tools in neurotransmitter research.
  • Possible combinations of agents include antiemetics, prokinetics, neuroleptics, antidepressants, neurokinin antagonists, anticonvulsants, histamine H1 receptor antagonists, ⁇ -blockers, ⁇ -agonists and ⁇ -antagonists, ergot alkaloids, weak analgesics, nonsteroidal anti-inflammatory drugs, corticosteroids, calcium Antagonists, 5-HT 1B / i D agonists or other antimigraine agents that co-exist with a or several inert customary carriers and / or diluents, for example with corn starch, milk sugar, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinyl pyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerol, water / sorbitol, water / polyethylene glycol, propylene glycol, Cetylstearylalkohol, carboxymethylcellulose or fatty substances such as hard fat or their suitable mixture
  • the non-steroidal anti-inflammatory drugs aceclofenac, acemetacin, acetylsalicylic acid, acetaminophen (paracetamol), azathioprine, diclofenac, diflunisal, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, leflunomide, lornoxicam, mefenamic acid are thus used as further active substances , Naproxen, phenylbutazone, piroxicam, sulfasalazine, zomepirac or their pharmaceutically acceptable salts as well as meloxicam and other selective COX2 inhibitors such as rofecoxib, valdecoxib, parecoxib, etoricoxib and celecoxib, as well as substances which inhibit earlier or later steps in the prostaglandin Inhibit synthesis or pros
  • CGRP antagonists with vanilloid receptor antagonists such as VR-1 antagonists, glutamate receptor antagonists such as mGlu5 receptor antagonists, Glu receptor antagonists, iGlu ⁇ receptor antagonists, AMPA receptor antagonists, purine receptor blockers such as P2X3 Antagonists, NO synthase inhibitors such as iNOS inhibitors, calcium channel blockers such as PQ-type blockers, N-type blockers, Potassium channel openers such as KCNQ channel openers, sodium channel blockers such as PN3 channel blockers, NMDA receptor antagonists, acid-sensing ion channel antagonists such as ASIC3 antagonists, bradykinin receptor antagonists such as B1 receptor antagonists, cannabinoid receptor agonists such as CB2 Agonists, CB1 agonists, somatostatin receptor agonists, such as sst2 receptor agonists.
  • VR-1 antagonists such as mGlu5 receptor antagonists, Glu receptor antagonists, iGlu ⁇ receptor antagonists,
  • the dose for these active substances is expediently 1/5 of the usually recommended lowest dosage up to 1/1 of the normally recommended dosage, so for example 20 to 100 mg sumatriptan.
  • the compounds according to the invention may be administered either alone or optionally in combination with other active substances for the treatment of migraine intravenously, subcutaneously, intramuscularly, intraarticularly, intrarectally, intranasally, by inhalation, topically, transdermally or orally, in particular aerosol formulations being suitable for inhalation.
  • the combinations may be administered either simultaneously or sequentially.
  • Suitable application forms are, for example, tablets, capsules, solutions, juices, emulsions or inhalable powders or aerosols.
  • the proportion of the pharmaceutically active compound (s) in each case in the range of 0.1 to 90 wt .-%, preferably 0.5 to 50 wt .-% of the total composition, i. in amounts sufficient to achieve the above dosage range.
  • Oral administration may be in the form of a tablet, as a powder, as a powder in a capsule (e.g., hard gelatin capsule), as a solution or suspension.
  • the active substance combination can be carried out as a powder, as an aqueous or aqueous-ethanolic solution or by means of a propellant gas formulation.
  • compositions are preferably characterized by the content of one or more of the compounds of the invention. It is particularly preferred if the compounds of the formula I are administered orally, it is particularly preferred if the administration takes place once or twice daily.
  • Corresponding tablets can be prepared, for example, by mixing the active substance (s) with known auxiliaries, for example inert diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrants, such as corn starch or alginic acid, binders, such as starch or gelatin, lubricants, such as magnesium stearate or talc, and / or means for achieving the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • the tablets can also consist of several layers.
  • Coated tablets can accordingly be produced by coating cores produced analogously to the tablets with agents customarily used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core can also consist of several layers.
  • Drageum cover to achieve a depot effect consist of several layers wherein the above mentioned in the tablets excipients can be used.
  • Juices of the active compounds or active compound combinations according to the invention may additionally contain a sweetening agent, such as saccharin, cyclamate, glycerol or sugar, and a taste-improving agent, e.g. Flavorings such as vanillin or orange extract. They may also contain suspending aids or thickening agents, such as sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
  • a sweetening agent such as saccharin, cyclamate, glycerol or sugar
  • a taste-improving agent e.g. Flavorings such as vanillin or orange extract.
  • suspending aids or thickening agents such as sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
  • the capsules containing one or more active ingredients or combinations of active substances can be prepared, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatine capsules.
  • suitable suppositories can be prepared, for example, by mixing with suitable carriers, such as neutral fats or polyethylene glycol or its derivatives.
  • AIs are, for example, water, pharmaceutically acceptable organic solvents, such as paraffins (eg petroleum fractions), oils of vegetable origin (eg peanut or sesame oil), mono- or polyfunctional alcohols (eg ethanol or glycerol), carriers such as natural minerals (eg kaolin, Clays, talc, chalk) synthetic minerals (eg finely divided silicic acid and silicates), sugars (eg pipe, milk and dextrose) emulsifiers (eg lignin, liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (eg magnesium stearate, talc, stearic acid and Sodium lauryl sulfate).
  • paraffins eg petroleum fractions
  • oils of vegetable origin eg peanut or sesame oil
  • mono- or polyfunctional alcohols eg ethanol or glycerol
  • carriers such as natural minerals (eg kaolin, Clays, talc, chalk) synthetic minerals (
  • the tablets may also contain additives other than those mentioned.
  • Sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatin and the like.
  • lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for tableting.
  • the active ingredients may be added to the abovementioned excipients with various flavor enhancers or dyes.
  • the compounds according to the invention are administered by inhalation, it is particularly preferred if the administration takes place once or twice daily.
  • the compounds according to the invention must be provided in inhalable dosage forms. Suitable inhalable dosage forms are inhalable powders, propellant-containing metered-dose inhalers or propellant-free inhalable solutions, which may be present in admixture with customary physiologically compatible excipients.
  • the compounds of general formula I can be prepared by methods known in principle. The methods listed in the "Handbook of Pharmaceutical Salts” (Eds. P. Heinrich Stahl, Camille G. Wermuth, Wiley-VHC 2002) have proven particularly useful. example 1
  • Example 15 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1 R) -1 - [(4-hydroxybenzyl) 3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2S, 3S) -2,3-dihydroxybutanedioate (3e)
  • FIG. 1 shows the X-ray powder diffractogram of the crystalline compound 1- [4-amino-3,5-dibromo- ⁇ / - [[4- (2,3,4,5-tetrahydro-2 (1H) -oxo-1,3] benzodiazepin-3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) piperidine p-toluenesulfonate (1 a).
  • FIG. 2 shows the X-ray powder diffractogram of the crystalline compound 1- [4-amino-3,5-dibromo- ⁇ / - [[4- (2,3,4,5-tetrahydro-2 (1 / - /) -oxo-1] , 3-benzodiazepin-3-yl) -1-piperidinyl] - carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) -piperidine-benzenesulfonate (1 b).
  • FIG. 3 shows the X-ray powder diffractogram of the crystalline compound 1- [4-amino-3,5-dibromo- ⁇ / - [[4- (2,3,4,5-tetrahydro-2 (1H) -oxo-1,3] benzodiazepin-3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) piperidine maleate (1c).
  • FIG. 4 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methyl-1-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl dimaleinate (2a).
  • FIG. 5 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrobromide (2b).
  • FIG. 6 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (?) -1 ( 4-amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester dihydrobromide (2c).
  • FIG. 7 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo)
  • FIG. 8 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (?) -1 ( 4-amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester difumarate (2e).
  • FIG. 9 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester disuccinate (2f).
  • FIG. 10 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - ( 4-Amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester sulfate (2g).
  • FIG. 1a shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1,2,4,5-tetrahydro-2-oxo-3 / -1,3-benzdiazepin-3-yl) - (1 R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide (3a) polymorph 1.
  • FIG. 11b shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzdiazepin-3-yl) - ( 1 R) -1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide (3a) polymorph 2 ,
  • FIG. 12a shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzdiazepin-3-yl) - (1 / ?) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrochloride (3b) polymorph 1.
  • FIG. 12a shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzdiazepin-3-yl) - (1 / ?) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholin
  • 12b shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / -1,3-benzdiazepin-3-yl) - (1R ) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydro-chloride (3b) polymorph 2.
  • FIG. 13 shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzdiazepin-3-yl) - (1R ) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester phosphate (3c).
  • FIG. 14 shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / -1,3-benzdiazepin-3-yl) - (1R ) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3R) -2,3-dihydroxybutanedioate (3d).
  • FIG. 15 shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzdiazepin-3-yl) - (1R ) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2S, 3S) -2,3-dihydroxybutanedioate (3e).
  • FIG. 16 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -hydroxy-3,5-dimethylbenzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) piperazin-1-yl] ethyl ester fumarate (4a).
  • FIG. 17 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -hydroxy-3,5-dimethyl-benzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) -piperazin-1-yl] -ethyl ester sulfate (4b).
  • FIG. 18 shows the X-ray powder diffractogram of the crystalline compound (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidine 1 -yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1, 4- dione hydrochloride pentahydrate (5a).
  • FIG. 18 shows the X-ray powder diffractogram of the crystalline compound (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidine 1 -yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl)
  • FIG. 20 shows the X-ray powder diffractogram of the crystalline compound (S) -2- (4-amino-3-chloro-5-trifluoromethylbenzyl) -1 - [4- (4-methylpiperazin-1-yl) piperidine 1 -yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1, 4- dion hydrobromide pentahydrate (5c).
  • FIG. 21 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid ⁇ (/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazine-1-yl] -2-oxo-ethyl ⁇ -amide-dimaleinate (6a).
  • FIG. 22 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid ⁇ (/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl ⁇ -amide-p-toluenesulfonate (6b).
  • FIG. 23 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid ⁇ (/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl ⁇ -amide-benzenesulfonate (6c).
  • FIG. 24 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid ⁇ (/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazine-1-yl] -2-oxo-ethyl ⁇ -amide-naphthalene-1,5-disulfonate (6d).
  • FIG. 25 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid ⁇ (/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl ⁇ -amide-naphthalene-2-sulfonate (6e ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne de nouveaux composés cristallins A de formule générale (I) dans laquelle A1, A2, A3, X, Y1, Y2 et Y3 ont les correspondances indiquées dans la revendication 1, et leurs sels tolérés d'un point de vue physiologique, avec des acides qui sont choisis dans la groupe B qui comprend l'acide chlorhydrique, l'acide bromhydrique, l'acide sulfurique, l'acide phosphorique, l'acide benzène-sulfonique, l'acide p-toluène-sulfonique, l'acide maléique, l'acide succinique, l'acide fumarique, l'acide tartrique dextrogyre, l'acide tartrique lévogyre, l'acide naphthaline-2-sulfonique et l'acide naphthaline-1,5-disulfonique, ainsi que leurs formes polymorphes, et les solvates et hydrates correspondants.
EP07727956A 2006-04-13 2007-04-11 Nouveaux composés cristallins Ceased EP2010513A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006017827A DE102006017827A1 (de) 2006-04-13 2006-04-13 Neue kristalline Verbindungen
PCT/EP2007/053488 WO2007118819A2 (fr) 2006-04-13 2007-04-11 Nouveaux composés cristallins

Publications (1)

Publication Number Publication Date
EP2010513A2 true EP2010513A2 (fr) 2009-01-07

Family

ID=38514672

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07727956A Ceased EP2010513A2 (fr) 2006-04-13 2007-04-11 Nouveaux composés cristallins

Country Status (20)

Country Link
US (1) US7638625B2 (fr)
EP (1) EP2010513A2 (fr)
JP (1) JP2009533387A (fr)
KR (1) KR20090007428A (fr)
CN (1) CN101421263A (fr)
AR (1) AR060442A1 (fr)
AU (1) AU2007239505A1 (fr)
BR (1) BRPI0710151A2 (fr)
CA (1) CA2648140A1 (fr)
CO (1) CO6140057A2 (fr)
DE (1) DE102006017827A1 (fr)
EA (1) EA200802049A1 (fr)
EC (1) ECSP088737A (fr)
MX (1) MX2008013158A (fr)
NO (1) NO20083709L (fr)
PE (1) PE20080735A1 (fr)
TW (1) TW200808767A (fr)
UY (1) UY30280A1 (fr)
WO (1) WO2007118819A2 (fr)
ZA (1) ZA200806859B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
PE20080370A1 (es) * 2006-06-08 2008-06-13 Boehringer Ingelheim Int Derivados de quinazolinona como antagonistas de cgrp
PT3254681T (pt) * 2012-02-27 2019-10-01 Bristol Myers Squibb Co Sal de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9- tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3- dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1- carboxilato
US20220249471A1 (en) * 2019-06-14 2022-08-11 The Regents Of The University Of California New therapeutic approach to lung disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0927192T3 (da) 1996-09-10 2004-09-13 Boehringer Ingelheim Pharma Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HILFIKER: "Polymorphism in the Pharmaceutical Industry", 2006, WILEY-VCH, Weinheim, ISBN: 3527311460, pages: 274 *
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts - Properties, Selection, and Use", 2002, WILEY-VCH, Weinheim, ISBN: 3906390268, pages: 191-193, 211-214, 308 *

Also Published As

Publication number Publication date
ZA200806859B (en) 2009-08-26
MX2008013158A (es) 2008-10-22
TW200808767A (en) 2008-02-16
CA2648140A1 (fr) 2007-10-25
CN101421263A (zh) 2009-04-29
ECSP088737A (es) 2008-10-31
WO2007118819A3 (fr) 2008-05-29
KR20090007428A (ko) 2009-01-16
US7638625B2 (en) 2009-12-29
UY30280A1 (es) 2007-11-30
JP2009533387A (ja) 2009-09-17
DE102006017827A1 (de) 2007-10-18
US20080086003A1 (en) 2008-04-10
PE20080735A1 (es) 2008-07-25
BRPI0710151A2 (pt) 2011-08-02
EA200802049A1 (ru) 2009-04-28
WO2007118819A2 (fr) 2007-10-25
CO6140057A2 (es) 2010-03-19
AU2007239505A1 (en) 2007-10-25
NO20083709L (no) 2008-10-31
AR060442A1 (es) 2008-06-18

Similar Documents

Publication Publication Date Title
DE68920482T2 (de) 1-Indolylalkyl-4-(substituierte Pyridinyl)-Piperazine.
DE69008012T2 (de) 4-Fluorbenzolderivate, Herstellungsverfahren und diese enthaltende pharmazeutische Zusammensetzungen.
DE60106287T2 (de) Chemische verbindungen
EP2438067B1 (fr) Spirolactames comme antagonistes du cgrp
EP1863799A1 (fr) Antagonistes cgrp, leur procédé de préparation ansi que leur utilisation comme médicaments
PL185029B1 (pl) Nowa 1-(1,2-dwupodstawiona-piperydynylo)-4-podstawiona pochodna piperazyny, kompozycja farmaceutyczna, sposób wytwarzania kompozycji farmaceutycznej i sposób wytwarzania 1-(1,2-dwupodstawionej-piperydynylo)-4-podstawionej pochodnej piperazyny
EP1228059B1 (fr) Nouveaux cyclopropanes utilises comme antagonistes de cgrp, medicaments contenant lesdits composes et procedes permettant de les preparer
EP1737842B1 (fr) Antagonistes cgrp selectionnes, leur procede de production et leur utilisation comme medicaments
WO2007036532A2 (fr) Antagonistes de cgrp selectionnes, procede pour les preparer et leur utilisation comme agents pharmaceutiques
DE69517027T2 (de) Serotonin 5-ht 1a-und dopamin d2-rezeptor liganden
DE69612753T2 (de) (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, verfahren zu seinerherstellung und dieses enthaltende medizinische zubereitung
EP2010513A2 (fr) Nouveaux composés cristallins
DE60112725T2 (de) Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors
EP2225236B1 (fr) Composés organiques
WO2007020261A2 (fr) Antagonistes cgrp selectionnes, leur procede de production et leur utilisation comme medicament
DE102005050892A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE69717969T2 (de) Substituierte n-methyl-n-(4-(piperidin-1-yl)-2-arylbutyl)-benzamide zur behandlung von allergischen erkrankungen
DE69634183T2 (de) Substituierte Heterocyclen
EP1992349B1 (fr) Antagonistes CGRP, leur préparation et leur utilisation comme médicament
DE69714579T2 (de) Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl-amino)-piperidin-1-yl)-2(aryl)butyl)benzamide zur behandlung von allergischen krankheiten
DE69024385T2 (de) Verbindung zur Behandlung von Störungen des Neurotransmittersystems im Gehirn
EP1770087A1 (fr) Antagonistes CGRP selectionnés, leur procedé de préparation ainsi que leur utilisation comme medicaments
WO2009043797A2 (fr) Nouveaux composés
EP1742939A2 (fr) Nouveaux composes alkyne a effet antagoniste de mch et medicaments contenant lesdits composes
WO2007028812A2 (fr) Antagonistes cgrp selectionnes, leur procede de production et leur utilisation comme medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17P Request for examination filed

Effective date: 20081201

RAX Requested extension states of the european patent have changed

Extension state: RS

Payment date: 20081201

Extension state: HR

Payment date: 20081201

Extension state: BA

Payment date: 20081201

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20110622

RAX Requested extension states of the european patent have changed

Extension state: RS

Payment date: 20081201

Extension state: BA

Payment date: 20081201

Extension state: HR

Payment date: 20081201

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130406